Tergene Biotech Profile
Key Indicators
- Authorised Capital ₹ 46.00 Cr
as on 15-06-2024
- Paid Up Capital ₹ 44.55 Cr
as on 15-06-2024
- Company Age 16 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.18 Cr
as on 15-06-2024
About Tergene Biotech
The Corporate was formerly known as Tergene Biotech Private Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 46.00 Cr and a paid-up capital of Rs 44.55 Cr.
The company has closed loans amounting to ₹1.18 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Tergene Biotech Limited India is Lonkari Sudhakar as CFO. Umesh Krishnamoorthy, Santhanam Subramanian, Kuppusamy Sathyan, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24230TG2008PLC113178
- Company No.
113178
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
07 Mar 2008
- Date of AGM
21 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Tergene Biotech?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Lonkari Sudhakar | CFO | 21-Mar-2022 | Current |
Mosuvan Kuppusamy  | Managing Director | 07-Mar-2008 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Umesh Krishnamoorthy | Director | 28-Jun-2023 | Current |
| Santhanam Subramanian | Director | 26-Aug-2016 | Current |
| Kuppusamy Sathyan | Whole-Time Director | 07-Mar-2008 | Current |
| Sivakumaran Meenakshisunderam | Director | 01-Apr-2015 | Current |
Financial Performance of Tergene Biotech.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Tergene Biotech?
Unlock access to Tergene Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Eugia Steriles Private LimitedActive 4 years 6 monthsSanthanam Subramanian and Sivakumaran Meenakshisunderam are mutual person
- Curateq Biologics Private LimitedActive 4 years 8 months
Sivakumaran Meenakshisunderam is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Biotechnology Industry Research Assistance Council Creation Date: 30 Aug 2012 | ₹1.18 Cr | Satisfied |
How Many Employees Work at Tergene Biotech?
Unlock and access historical data on people associated with Tergene Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tergene Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tergene Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
